|Bid||24.42 x 500|
|Ask||25.80 x 1500|
|Day's Range||24.15 - 24.80|
|52 Week Range||18.03 - 32.50|
|PE Ratio (TTM)||49.98|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.63|
Exelixis, Inc. today announced it has completed the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for CABOMETYX® tablets as a treatment for patients with previously treated advanced hepatocellular carcinoma .
Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the
Stocks are under fresh pressure after new Federal Reserve chairman Jerome Powell sounded a hawkish note in his first appearance before Congress this week. The odds of four quarter-point rate hikes is now rising fast, pressuring long-term Treasury yields higher, bringing back the headwind that pushed stocks into a correction earlier this month.
Exelixis and Clovis shares diverged Tuesday after each reported lackluster sales of their biggest cancer drugs in the fourth quarter.
Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.
Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.
Exelixis, Inc. today announced that its partner Daiichi Sankyo Company, Limited has submitted its regulatory application for esaxerenone as a treatment for patients with hypertension to the Japanese Pharmaceutical and Medical Devices Agency.
On a per-share basis, the South San Francisco, California-based company said it had net income of 12 cents. The results matched Wall Street expectations. The average estimate of eight analysts surveyed ...
Exelixis reported 12 cents earnings per share on $120.1 million in sales for the fourth quarter.
Exelixis, Inc. today reported financial results for the fourth quarter and full year of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Exelixis, Inc. (NASDAQ: EXEL ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 26, 2018 at 5:00 PM Eastern Time. ...
Exelixis (NASDAQ: EXEL ) will be releasing its next round of earnings Monday. For all of the relevant information, here is your guide for today's Q4 earnings announcement. Earnings and Revenue Wall Street ...
Exelixis Inc (NASDAQ:EXEL) is trading with a trailing P/E of 57.2x, which is higher than the industry average of 28.1x. While EXEL might seem like a stock to avoid orRead More...
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / U.S. markets spiked to session highs after minutes from the Fed's January meeting were released, but then dropped as yields for the 10-year Treasury note ...
Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.
Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.